Noah Labs selected for highly competitive EIC Accelerator program

Noah Labs, a digital health company specializing in AI-based telemonitoring and voice diagnostics for cardiovascular disease, has been selected for the prestigious European Innovation Council (EIC) Accelerator program. This milestone positions Noah Labs among Europe’s most promising deep tech startups.

In the most competitive funding round to date, only 71 companies were selected from 1,211 applications - a success rate of just 6%. Noah Labs is one of just 15 companies from Germany to receive this support.

As part of the EIC Accelerator, Noah Labs will receive up to €11 million in blended financing. This includes a €2.5 million non-dilutive grant, as well as up to €8.5 million in potential equity investment from the EIC Fund. In addition to funding, the program provides access to the EIC’s Business Acceleration Services connecting selected companies with industry partners, investors, and leading experts across Europe.

‍

Advancing AI-powered voice biomarkers in cardiology

The funding will support the continued development and clinical validation of Noah Labs’ breakthrough voice-based early warning system for heart failure the leading cause of hospitalizations worldwide.

Co-founder and CEO Oliver Piepenstock explains:

‍

“We thank the EIC for their trust and support. Being selected as one of just a few German startups reinforces our belief in the transformative power of voice-based diagnostics. Our AI technology turns the human voice into a non-invasive biomarker to detect heart failure before hospitalization is needed. This funding enables us to expand our research, strengthen our product development, and scale our impact on patient care.”

‍

A validated platform for remote cardiovascular care

Noah Labs’ core product, Noah Labs Ark, is already approved as a Class IIa medical device under the EU Medical Device Regulation (MDR). It enables remote monitoring of chronic cardiovascular conditions such as heart failure, hypertension, and arrhythmia by collecting and analyzing real-time vital data from approved medical devices. Doctors are alerted to changes in patient health before clinical deterioration occurs.

With the EIC Accelerator support, Noah Labs aims to further enhance the Ark platform, expand clinical use cases, and prepare for international growth.

‍

About Noah Labs

Founded in 2021, Noah Labs develops AI-powered solutions for cardiovascular care. Its technologies include the MDR-certified Noah Labs Ark platform for remote patient monitoring and a proprietary voice analysis solution currently under clinical validation with partners such as the Charité Berlin, Mayo Clinic, and university hospitals in Maastricht and Barcelona. Noah Labs is ISO 13485 certified and currently employs 25 employees in Berlin and Potsdam.